Evidence map›Paper›PMID 42096089›Full record

ArticleVirchows Archiv : an international journal of pathology2026

ER, PR, and HER2 triple positivity and triple negativity are associated with adverse prognostic significance in endometrial serous carcinoma.

Zhenwei Zhang, Tahreem A Karim, Liang Cheng, Kamaljeet Singh, M Ruhul Quddus

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhenwei ZhangDepartment of Pathology and Laboratory Medicine, Women & Infants Hospital of Rhode Island and The Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence RI, 02905, USA. zhenwei.zhang@vumc.org.
Tahreem A KarimSchool of Data Science, University of Michigan School of Information, Ann Arbor, MI, USA.
Liang ChengDepartment of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, Legorreta Cancer Center at Brown University, Brown University Health, Providence, RI, USA.
Kamaljeet SinghDepartment of Pathology and Laboratory Medicine, Women & Infants Hospital of Rhode Island and The Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence RI, 02905, USA.
M Ruhul QuddusDepartment of Pathology and Laboratory Medicine, Women & Infants Hospital of Rhode Island and The Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence RI, 02905, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial serous carcinoma (ESC) is an aggressive tumor of the mullerian system. The prognostic significance of the combined status of HER2, estrogen receptor (ER), and progesterone receptor (PR) on ESC's survival and clinicopathologic outcome remains inadequately reported and understood. In this study, we retrospectively analyzed sixty-one ESC cases diagnosed at our institution between January 2017 and April 2024 for overall survival outcomes and pathologic presentation. Most ESC cases were ER-positive (n = 53, 87%) and PR-positive (n = 42, 69%), while HER2 was positive in 43% of cases (n = 26). Subclassification based on the combined status of ER, PR and HER2 revealed significant heterogeneity of overall survival within both HER2-positive and negative groups. Notably, the triple-positive subgroup had the shortest median survival and poorer prognosis than the other subgroups (p = 0.04; median survival: 394 vs. 676.5 days). The triple-negative subgroup demonstrated significantly worse overall survival as well. The unfavorable clinical outcome in these subgroups was associated with a higher frequency of lower uterine segment, cervical, and lymph node involvement. This study demonstrates that combined HER2, ER, and PR status provides valuable prognostic information in ESC, enabling the identification of subgroups with distinct clinical behaviors. Stratification based on combined receptor status may facilitate more personalized treatment approaches and improve clinical outcomes in this aggressive malignancy. Further large-scale studies are needed to validate these findings and explore targeted therapeutic strategies for high-risk subgroups.

Indexed as

Endometrial serous carcinomaEstrogen receptorHer2/neu positiveProgesterone receptorPrognostic factors

Identifiers

PMID42096089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.